NCT05312151

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: COMPASS Pathways · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder

Detailed description

The Safety and Tolerability of COMP360 administered under supportive conditions in participants with Post-traumatic Stress Disorder

Conditions

• Post Traumatic Stress Disorder

Interventions

Type	Name	Description
DRUG	Psilocybin	Open label

Timeline

• Start date: 2022-06-10
• Primary completion: 2024-02-12
• Completion: 2024-02-12
• First posted: 2022-04-05
• Last updated: 2025-06-13
• Results posted: 2025-06-13

Locations

3 sites across 2 countries: United States, United Kingdom

Regulatory

• FDA-regulated drug study